Ocular changes resulting from therapy with amiodarone.
Amiodarone, a powerful antiarrhythmic agent recently made available in Britain, is known to cause corneal changes, but the clinical implications of this unwanted effect are still controversial. We have made serial observations on 105 patients treated with the drug for periods ranging from 3 months to over 7 years. Corneal abnormalities were detected by slit-lamp examination in 103 patients (98%). These always progressed over several months but subsequently showed a stable pattern which changed only with alteration of dose. The abnormalities regressed and disappeared within 7 months in the 16 patients whose treatment was discontinued for reasons unconnected with ocular changes. No macular changes or permanent sequelae occurred. Ocular symptoms were unusual: 6 patients had reactions in the skin of the eyelids, and 6 others had minor symptoms related to the corneal changes. We do not believe that ophthalmological surveillance is mandatory in asymptomatic patients on long-term amiodarone therapy.
D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001572:Benzofurans / Q000009:adverse effects*; D003316:Corneal Diseases / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D005141:Eyelid Diseases / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D013997:Time Factors; D014792:Visual Acuity
D001572:Benzofurans; D000638:Amiodarone